Skip to main content
. 2018 Aug 2;4(11). doi: 10.1001/jamaoncol.2018.2969

Figure 4. Acquired Resistance to Osimertinib in a Validation Cohort (n = 110) From the AURA Trial.

Figure 4.

A, This Kaplan-Meier curve shows that, in 110 patients, those with T790M loss had a median time to treatment discontinuation (TTD) of 5.5 months, which was lower than patients who were T790M-positive and C797S-negative (median, 12.6 months) or T790M-positive and C797S-positive (median, 12.4 months). B, A higher percentage of patients with short TTD (68%) had T790M loss; a higher percentage of patients with long TTD (72%) maintained T790M.